- Home
- VGI vs MAIA Comparison
VGI vs MAIA Comparison
Compare VGI & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGI | MAIA |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.1M | 44.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | VGI | MAIA |
|---|---|---|
| Price | $7.85 | $1.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.0K | ★ 994.9K |
| Earning Date | 01-01-0001 | 11-07-2025 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.68 | $0.87 |
| 52 Week High | $7.99 | $2.74 |
Technical Indicators
Market Signals| Indicator | VGI | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 62.60 |
| Support Level | $7.73 | $1.13 |
| Resistance Level | $7.86 | $1.75 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 53.53 | 63.71 |
Price Performance
Historical ComparisonAbout VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.